121 related articles for article (PubMed ID: 7630318)
1. Comparison of chromogranin A and pancreastatin levels in plasma of patients with pancreatic islet cell tumor.
Tateishi K; Kitayama N; Matsuoka Y; Funakoshi A
Life Sci; 1995; 57(9):889-95. PubMed ID: 7630318
[TBL] [Abstract][Full Text] [Related]
2. Comparison of plasma pancreastatin and GAWK concentrations, presumed processing products of chromogranin A and B, in plasma of patients with pancreatic islet cell tumors.
Yasuda D; Iguchi H; Funakoshi A; Wakasugi H; Sekiya K; Misawa T; Tateishi K; Bloom SR; Nawata H
Horm Metab Res; 1993 Nov; 25(11):593-5. PubMed ID: 8288164
[TBL] [Abstract][Full Text] [Related]
3. Plasma pancreastatin-like immunoreactivity in various diseases.
Tateishi K; Funakoshi A; Wakasugi H; Iguchi H; Shinozaki H; Abe M; Funakoshi S; Tamamura H; Yajima H; Matsuoka Y
J Clin Endocrinol Metab; 1989 Dec; 69(6):1305-8. PubMed ID: 2555388
[TBL] [Abstract][Full Text] [Related]
4. Production and secretion of chromogranin A and pancreastatin by the human pancreatic carcinoma cell line QGP-1N on stimulation with carbachol.
Kitayama N; Tateishi K; Funakoshi A; Kono A; Matsuoka Y
Regul Pept; 1994 Aug; 52(3):195-203. PubMed ID: 7800852
[TBL] [Abstract][Full Text] [Related]
5. Measurements of chromogranin A, chromogranin B (secretogranin I), chromogranin C (secretogranin II) and pancreastatin in plasma and urine from patients with carcinoid tumours and endocrine pancreatic tumours.
Stridsberg M; Oberg K; Li Q; Engström U; Lundqvist G
J Endocrinol; 1995 Jan; 144(1):49-59. PubMed ID: 7891024
[TBL] [Abstract][Full Text] [Related]
6. Chromogranin A and pancreastatin-like immunoreactivity in serum of gastrinoma patients.
Syversen U; Mignon M; Bonfils S; Kristensen A; Waldum HL
Acta Oncol; 1993; 32(2):161-5. PubMed ID: 8323758
[TBL] [Abstract][Full Text] [Related]
7. Chromogranin A plasma concentration and expression in pancreatic islet cell tumors of dogs and cats.
Myers NC; Andrews GA; Chard-Bergstrom C
Am J Vet Res; 1997 Jun; 58(6):615-20. PubMed ID: 9185968
[TBL] [Abstract][Full Text] [Related]
8. Immunoassays for measurement of chromogranin A and pancreastatin-like immunoreactivity in humans: correspondence in patients with neuroendocrine neoplasia.
Syversen U; Jacobsen MB; O'Connor DT; Rønning K; Waldum HL
Neuropeptides; 1994 Mar; 26(3):201-6. PubMed ID: 8208366
[TBL] [Abstract][Full Text] [Related]
9. Pancreastatin producing cell line from human pancreatic islet cell tumor.
Funakoshi A; Tateishi K; Tsuru M; Jimi A; Wakasugi H; Ikeda Y; Kono A
Biochem Biophys Res Commun; 1990 Apr; 168(2):741-6. PubMed ID: 2159299
[TBL] [Abstract][Full Text] [Related]
10. Validation of serum versus plasma measurements of chromogranin a levels in patients with carcinoid tumors: lack of correlation between absolute chromogranin a levels and symptom frequency.
Woltering EA; Hilton RS; Zolfoghary CM; Thomson J; Zietz S; Go VL; Vinik AI; Vinik E; O'Dorisio TM; Mamikunian G
Pancreas; 2006 Oct; 33(3):250-4. PubMed ID: 17003646
[TBL] [Abstract][Full Text] [Related]
11. Regulation of pancreastatin release from a human pancreatic carcinoid cell line in vitro.
Jeng YJ; Townsend CM; Nagasawa S; Chuo S; Kern K; Yanaihara N; Ferrar RS; Hill FL; Thompson JC; Greeley GH
Endocrinology; 1991 Jan; 128(1):220-5. PubMed ID: 1702700
[TBL] [Abstract][Full Text] [Related]
12. Neuroendocrine differentiation in carcinomas of the prostate: do neuroendocrine serum markers reflect immunohistochemical findings?
Angelsen A; Syversen U; Haugen OA; Stridsberg M; Mjølnerød OK; Waldum HL
Prostate; 1997 Jan; 30(1):1-6. PubMed ID: 9018329
[TBL] [Abstract][Full Text] [Related]
13. Neuroendocrine differentiation in colorectal carcinomas.
Syversen U; Halvorsen T; Mårvik R; Waldum HL
Eur J Gastroenterol Hepatol; 1995 Jul; 7(7):667-74. PubMed ID: 8590163
[TBL] [Abstract][Full Text] [Related]
14. The immunomodulatory functions of chromogranin A-derived peptide pancreastatin.
Ioannidis M; Mahata SK; van den Bogaart G
Peptides; 2022 Dec; 158():170893. PubMed ID: 36244579
[TBL] [Abstract][Full Text] [Related]
15. Prohormone convertase-1 is essential for conversion of chromogranin A to pancreastatin.
Udupi V; Lee HM; Kurosky A; Greeley GH
Regul Pept; 1999 Sep; 83(2-3):123-7. PubMed ID: 10511466
[TBL] [Abstract][Full Text] [Related]
16. Chromogranin A and chromogranin B are sensitive circulating markers for phaeochromocytoma.
Stridsberg M; Husebye ES
Eur J Endocrinol; 1997 Jan; 136(1):67-73. PubMed ID: 9037129
[TBL] [Abstract][Full Text] [Related]
17. A multianalyte PCR blood test outperforms single analyte ELISAs (chromogranin A, pancreastatin, neurokinin A) for neuroendocrine tumor detection.
Modlin IM; Drozdov I; Alaimo D; Callahan S; Teixiera N; Bodei L; Kidd M
Endocr Relat Cancer; 2014 Aug; 21(4):615-28. PubMed ID: 25015994
[TBL] [Abstract][Full Text] [Related]
18. Elevated plasma levels of pancreastatin (PST) in patients with non-insulin-dependent diabetes mellitus (NIDDM).
Funakoshi A; Tateishi K; Shinozaki H; Matsumoto M; Wakasugi H
Regul Pept; 1990 Sep; 30(2):159-64. PubMed ID: 2274680
[TBL] [Abstract][Full Text] [Related]
19. Downregulation of prohormone convertase-1 by a phorbol ester.
Udupi V; Townsend CM; Gomez G; Zhang T; Greeley GH
Biochem Biophys Res Commun; 1995 Dec; 217(2):495-500. PubMed ID: 7503727
[TBL] [Abstract][Full Text] [Related]
20. A phylogenetic survey of pancreastatin and chromogranin immunoreactivity in chromaffin (TH-, DBH-, and PNMT-immunoreactive) cells of the adrenal organ of vertebrates.
Reinecke M; Maake C
Gen Comp Endocrinol; 1993 May; 90(2):251-65. PubMed ID: 8100544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
